{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"6.000","floor":"4.540"},"ipodate":{"start":"2011-04-08 00:00:00","end":"2011-04-13 00:00:00"},"minimumcapital":"3030.24","subscribed":"5.88","marketcap":"49.12億","H_marketcap":"--","pe":"--","codesrate":"90.03","link":"https://staticpdf.iqdii.com/stockdata/notice/Prospectus/01011/LTN20110408054_C.pdf","ipopricing":"4.540","resultdate":"2011-04-19 00:00:00","enddate":"2011-04-13 00:00:00","listeddate":"2011-04-20 00:00:00","issuenumber":"35703.20萬","issuenumberhK":"3570.35萬","issuenumberother":"32132.85萬","grayprice":"--","sponsors":"瑞士銀行香港分行","raisemoney":"107030.00萬","use":"1、約25%或267.6百萬港元，將主要用于透過自然發 展及合并與收購的方式擴展及提升我們的分銷網絡（以疫苗業務為主）。 ；\n2、約25%或267.6百萬港元，將用于提升及擴展我們的基礎設施；\n3、約10%或107.1百萬港元，將用作擴充我們的疫苗及藥品推廣團隊；\n4、約20%或214.0百萬港元，將用作透過取得其他疫苗及藥品分銷及／或推廣權特許權擴展我們產品的投資組合；\n5、約20%或214.0百萬港元，將用于向知名的海外供應商采購進口疫苗或藥品。","shares":500,"leadagent":"瑞士銀行香港分行,高盛(亞洲)有限責任公司","bookrunners":"瑞士銀行香港分行,高盛(亞洲)有限責任公司","coordinator":"瑞士銀行香港分行","firstDayOpen":"4.20","IsEiio":0,"Interestdays":6,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"瑞士銀行香港分行","code":"E01011","name":"泰凌醫藥","fullname":"中國泰凌醫藥集團有限公司"},"institutioninfo":{"principaloffice":"香港上環威靈頓街198號威靈頓大廈28樓","registrars":"卓佳證券登記有限公司","registrarstel":"(852) 2980 1333","chairman":"吳鐵","secretary":"彭永康","telephone":"(852) 2808 1606","substantialshareholders":"吳鐵及家族成員(31.89%),Shanghai Jiao Da Only Co., Ltd.(22.28%)","principalactivities":"生產、銷售及分銷醫藥及疫苗產品，以及向供應商提供市場推廣及宣傳服務。","website":"http://www.ntpharma.com"},"managerinfo":[],"investorinfo":[],"TotalShareholdingPercentage":0},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":508}